MX2018012945A - Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre. - Google Patents

Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.

Info

Publication number
MX2018012945A
MX2018012945A MX2018012945A MX2018012945A MX2018012945A MX 2018012945 A MX2018012945 A MX 2018012945A MX 2018012945 A MX2018012945 A MX 2018012945A MX 2018012945 A MX2018012945 A MX 2018012945A MX 2018012945 A MX2018012945 A MX 2018012945A
Authority
MX
Mexico
Prior art keywords
dosage regimens
antibodies
dendritic cell
cell antigen
pharmaceutical compositions
Prior art date
Application number
MX2018012945A
Other languages
English (en)
Inventor
Martin David
R H Krebs Mark
Dai David
Sule Shantanu
Rabah Dania
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2018012945A publication Critical patent/MX2018012945A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

|Se proporcionan formulaciones y regímenes de dosificación de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre (BDCA"). Estas formulaciones y régimenes de dosificación se usan en el tratamiento de trastornos asociados al BDCA2 tales como el lupus aritematoso sistémico, lupus eritematoso cutáneo y lupus aritematoso discoide, así como el síndrome de liberación de citosinas.
MX2018012945A 2016-04-28 2017-04-27 Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre. MX2018012945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Publications (1)

Publication Number Publication Date
MX2018012945A true MX2018012945A (es) 2019-03-06

Family

ID=58672794

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012945A MX2018012945A (es) 2016-04-28 2017-04-27 Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.
MX2023008075A MX2023008075A (es) 2016-04-28 2018-10-23 Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023008075A MX2023008075A (es) 2016-04-28 2018-10-23 Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre.

Country Status (15)

Country Link
US (1) US20190284281A1 (es)
EP (1) EP3448425A1 (es)
JP (3) JP7045327B2 (es)
KR (3) KR20240033168A (es)
CN (2) CN116850282A (es)
AU (1) AU2017258191A1 (es)
BR (1) BR112018072125A2 (es)
CA (1) CA3022116A1 (es)
CO (1) CO2018012506A2 (es)
EA (1) EA201892443A1 (es)
IL (1) IL262514A (es)
MA (1) MA44763A (es)
MX (2) MX2018012945A (es)
PH (1) PH12018502278A1 (es)
WO (1) WO2017189827A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040671A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
TW202222829A (zh) * 2020-12-03 2022-06-16 美商百健Ｍａ公司 治療皮膚型紅斑狼瘡及全身性紅斑狼瘡之方法
KR20230022786A (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
MX363407B (es) * 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.

Also Published As

Publication number Publication date
IL262514A (en) 2018-12-31
EP3448425A1 (en) 2019-03-06
KR20190002563A (ko) 2019-01-08
AU2017258191A1 (en) 2018-11-15
KR102366547B1 (ko) 2022-02-23
US20190284281A1 (en) 2019-09-19
KR20240033168A (ko) 2024-03-12
BR112018072125A2 (pt) 2019-03-19
CN109475623B (zh) 2023-05-26
CA3022116A1 (en) 2017-11-02
KR20220028150A (ko) 2022-03-08
CN116850282A (zh) 2023-10-10
MX2023008075A (es) 2023-07-18
MA44763A (fr) 2019-03-06
CN109475623A (zh) 2019-03-15
JP7045327B2 (ja) 2022-03-31
EA201892443A1 (ru) 2019-04-30
WO2017189827A1 (en) 2017-11-02
JP2024038308A (ja) 2024-03-19
JP2022084782A (ja) 2022-06-07
JP2019520316A (ja) 2019-07-18
PH12018502278A1 (en) 2019-09-09
CO2018012506A2 (es) 2018-12-14

Similar Documents

Publication Publication Date Title
PH12018502278A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
PH12020500238A1 (en) Cytokine conjugates for the treatment of proliferative and infectious diseases
PH12017500803A1 (en) Anti-pd-1 antibodies
WO2016081518A3 (en) Engineered gamma delta t-cells
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2016105542A3 (en) Nanoparticle compositions and methods for immunotherapy
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MA40539A (fr) Procédés de formulation de compositions de conjugués anticorps-médicaments
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
WO2016004213A3 (en) Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения